A randomized trial suggests that briefly holding certain biologic or JAK inhibitor therapies after a supplemental COVID-19 vaccine dose increased short-term inflammatory arthritis flares without significantly improving the measured anti–receptor-binding-domain antibody response. The findings do not support routinely interrupting the studied therapies solely to boost that antibody measure.

Why It Matters To Your Practice

• Clinicians are often asked whether pausing immunomodulatory therapy around COVID-19 vaccination improves vaccine response enough to justify flare risk.

• In the COVER trial, 840 patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis were randomized to continue therapy or hold a TNF inhibitor, interleukin-17 inhibitor, abatacept, or a JAK inhibitor for two weeks after vaccination, making this directly relevant to common rheumatology decisions around supplemental doses.

Clinical Implications

• Participants assigned to hold therapy had higher odds of flare or disease worsening than those assigned to continue treatment, with an odds ratio of 2.27 and a 95% confidence interval of 1.41 to 3.65.

• Among 509 participants who completed an interim flare questionnaire at a median of 10 days, clinically important worsening was reported by 21.1% in the hold group versus 9.1% in the continue group, indicating a meaningful short-term tradeoff for some patients even though group differences were no longer seen at the questionnaire threshold by six weeks.

• The strongest practical message is operational rather than prescriptive: medication-hold decisions should be individualized based on baseline disease control, prior flare history, and the consequences of a short loss of control. Cytokine profiling has not been clinically validated to predict who will flare after this specific two-week post-vaccination hold.

Insights

• The leading explanation for higher flare risk is temporary loss of disease control when anti-inflammatory treatment is interrupted, not a mechanism proven by COVER.

• An exploratory analysis suggested the flare signal was most pronounced among JAK inhibitor users and in shorter-half-life treatment groups, but that cannot disentangle drug half-life, drug class, or patient characteristics and should not be treated as definitive drug-specific evidence.

• Vaccination-related immune activation as a contributor remains hypothetical. Because both groups in COVER were vaccinated, the trial cannot determine whether vaccine-triggered immune responses contributed to the difference, and post-vaccination symptoms can overlap with flare symptoms.

• Evidence on biomarker prediction is limited. COVER did not test a cytokine panel, and studies of biomarkers from longer-term biologic tapering or withdrawal cannot be directly applied to a brief two-week hold around vaccination. Observational registry data linked active disease and reducing or stopping antirheumatic medication with higher flare odds, but those findings do not provide a validated individual prediction tool.

The Bottom Line

• For the biologic and JAK inhibitor strategies studied in COVER, a two-week post-vaccination hold increased short-term flare risk and did not significantly improve the measured antibody response.

• There is no clinically validated cytokine-based method to identify which patients can safely hold therapy in this setting.

• If a hold is considered, the decision is best individualized rather than routine.

References:

Antiviral Chewing Gum Cuts Risk of Certain Head and Neck Cancers to Almost Zero in New Study

Orthogonal Fc engineering enables multiplexed delivery of mRNA-encoded bispecific antibodies that constrain viral escape

Rurality as a Risk Factor for Excess Mortality in Nebraska During the COVID-19 Pandemic